Medicine and product identity · C-012
Semaglutide: licensed medicine versus research-labelled vial
One molecule name can sit under two quality regimes. Human evidence supports specific authorised semaglutide medicines for defined uses. It does not verify a research-labelled powder or vial sold online.
Semaglutide is the active substance in authorised UK prescription medicines, including Wegovy for weight management in eligible people. A research-labelled semaglutide vial is not the same product. Its name does not establish identity, amount, formulation, sterility, storage history or equivalence to evidence from licensed medicines.
Pain that may spread to the back, with or without nausea or vomiting, can indicate acute pancreatitis. Use NHS 111, A&E or 999 as appropriate. Sudden or rapidly worsening eyesight also needs urgent medical assessment.
Claim-level evidence
The classification changes with the question. There is no single semaglutide badge that answers medicine efficacy, vial identity and product safety at once.
Weight management with an authorised medicine
Relevant human evidence. In STEP 1, 1,961 adults with overweight or obesity and without diabetes were randomised to semaglutide or placebo alongside lifestyle intervention. Mean body-weight change at 68 weeks was about 14.9% with semaglutide and 2.4% with placebo. The finding belongs to the studied medicine, population and protocol.
Known adverse effects and safety monitoring
Relevant human and pharmacovigilance evidence. Gastrointestinal effects are common. The MHRA has strengthened warnings about acute pancreatitis across GLP-1 and dual GLP-1/GIP receptor agonists. UK product information also contains medicine-specific contraindications, precautions and adverse-effect information.
Identity and quantity of a research-labelled vial
No reliable evidence from the label alone. The word “semaglutide” does not confirm what the vial contains or how much. Identity needs a suitable specific method and reference. Quantity needs a separate validated assay. Read how identity is actually confirmed.
Clinical equivalence of an online vial
No reliable evidence identified. Equivalence would require evidence for identity, strength, formulation, impurities, microbiological quality, stability and performance. A seller certificate that covers one attribute cannot establish the full product.
The molecule name does not carry the medicine with it
| Question | Authorised semaglutide medicine | Research-labelled vial |
|---|---|---|
| Legal status | Prescription-only medicine with a defined UK authorisation and indication. | Not an authorised presentation for treatment. Powder requiring mixing is not an authorised UK GLP-1 product. |
| Product identity | Finished product and active substance sit within regulated manufacturing and batch-release controls. | Identity is a seller claim until supported by suitable testing of a linked sample. |
| Strength and formulation | Specified in current product information and controlled for each released batch. | Stated amount and formulation may be unverified. Purity is not quantity. |
| Sterility and endotoxin | Parenteral quality controls apply within the authorised product system. | These require separate evidence. An identity or purity result cannot establish either. |
| Clinical use | Prescribing follows an assessment, indication, contraindications and follow-up. | The seller may offer no legitimate clinical assessment or monitoring. |
| Safety reporting | Yellow Card reporting and manufacturer pharmacovigilance support signal detection. | The seller may be anonymous, overseas or unable to investigate the batch. |
For the complete route comparison, see licensed supply versus a research-labelled vial.
Counterfeit risk is a product problem
The MHRA has received reports of counterfeit pre-filled pens sold as weight-loss medicines. A pack can copy a brand, presentation or batch reference while containing another substance or an unknown quantity. Visual inspection alone cannot clear it.
There are two distinct failure modes. An unauthorised research vial may never claim to be a licensed pack. A counterfeit tries to imitate a recognised medicine. Both can sever the link between clinical evidence and the product in hand.
Read documented counterfeit and unauthorised GLP-1 incidents and preserve packaging, seller details and payment records if you need to report a suspected product.
Known medicine risks and unknown product risks
Semaglutide safety information comes from trials, authorised use and pharmacovigilance. These sources can describe recognised adverse effects and emerging signals for regulated medicines. The MHRA advises urgent medical help for severe, persistent abdominal pain because acute pancreatitis has been reported with GLP-1 medicines. It also advises urgent assessment for sudden or rapidly worsening eyesight following very rare reports of non-arteritic anterior ischaemic optic neuropathy with semaglutide.
An unverified vial adds another uncertainty layer. Substitution, incorrect quantity, contamination, temperature damage or a missing ingredient can cause problems that authorised-medicine data does not predict. Keep known risks separate from risks that have not been measured.
Research record added 6 September 2026. The GLP-1 impurity-study record explains what the laboratory paper can contribute to product-quality checking and which questions remain outside its scope.
Source ledger
Primary sources checked on 7 August 2026.
- Wegovy Summary of Product Characteristics · current UK indication, presentation, contraindications, warnings and adverse effects.
- STEP 1 trial, New England Journal of Medicine · randomised human weight-management evidence.
- MHRA patient guidance · prescription route, unauthorised vials, counterfeits and urgent symptoms.
- MHRA Drug Safety Update on acute pancreatitis · strengthened warning, 29 January 2026.
Editorial method: We record medicine evidence and product evidence on separate lines. A clinical result transfers only to the authorised product and conditions it can support.
Continue the comparison
Questions people ask
Is semaglutide authorised in the UK?
Specific semaglutide medicines are authorised for defined indications and are prescription-only. Authorisation belongs to the named product, formulation, presentation and conditions in its product information. It does not extend to powder or research-labelled vials sold online.
Can mass spectrometry prove that a vial is Wegovy?
No. A suitable mass-spectrometry result may support the identity of a tested sample. It does not establish the full formulation, quantity, sterility, endotoxin status, stability, authorised manufacture or equivalence to Wegovy.
Do Yellow Card reports prove semaglutide caused an event?
No. Yellow Card reports record suspicions and help detect safety signals. They do not prove causation, establish incidence or show that every report involved a genuine authorised product. Regulators assess reports alongside exposure, clinical data and other evidence.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-012, Semaglutide: licensed medicine versus research-labelled vial was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 10 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Research reference checked and reviewed · 6 September 2026. Scientific review: Eleni Kiromitis. Clinical review: Dr Stavroula Nikitopoulou. The existing evidence verdict is unchanged; earlier sources retain their own check dates.